ACG San Diego | M&A as Fundraising for San Diego Life Science Companies: The Cend Therapeutics and Caladrius Biosciences Transaction

Paul helps entrepreneurs and their investors get companies formed, funded and sold, including initial formation of corporations and LLCs, negotiation of seed, early and mid-stage equity financings and buy and sell-side mergers and acquisitions. He is also adept at venture capital investments, public and private securities offering and compliance and general business counseling. Paul has also counseled some of San Diego’s most successful companies in Securities and Exchange Commission compliance and general corporate governance.

Mr. Slack is an industry veteran with over 25 years’ experience in public and private biotech as well as large pharmaceutical companies. He has been responsible for numerous company financings, strategic alliances and other partnerships. He joined the Cend Therapeutics’ Board in October 2019 and was appointed President and CEO in June 2020. Most recently, David served as co-founding Chief Business Officer at Viracta Therapeutics. Previously, David served as Vice President for Business Development at leading antisense drug company, Ionis Pharmaceuticals. David served in senior management positions as Rhône-Poulenc Rorer, RPR Gencell and Aventis Pharmaceuticals.